The EuroTARGET cohort: A European project on TArgeted therapy in renal cell cancer-GEnetic- and tumor-related biomarkers for response and toxicity

EuroTARGET is a European collaborative project designed as an observational study for which patients with mRCC were recruited prospectively in 62 centers. In total, 1,210 patients with mRCC were included. Of these, 920 received a tyrosine kinase inhibitor as first-line targeted treatment (sunitinib, sorafenib or pazopanib) and had at least 6 months of outcome assessment (median follow-up 15.3 months). Detailed clinical information (baseline and follow-up) from all patients was entered in web-based case record forms. Blood was collected for germline DNA and pharmacokinetic/pharmacodynamic analyses and, where available, fresh-frozen tumor material was collected to perform tumor DNA, RNA, kinome, and methylome analyses.